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Abstract
Background: An outbreak of Candida auris began globally in 2014 including Pakistan and since then it has
emerged as a nosocomial multi-drug resistant pathogen. The aim of this study was to assess the clinical spectrum
and outcome of patients, from a single center in Pakistan, in whom C. auris was isolated.
Methods: A retrospective study was conducted on 92 patients; ≥16 years with at least one culture positive for C.
auris, at the Aga Khan University Hospital Karachi, Pakistan from Sept 2014-Mar 2017.Demographics, clinical history,
management and outcome were studied. A logistic regression model was used to identify the risk factors for
mortality.
Results: We identified 92 patients with C. auris (193 isolates), of whom 52.2% were males. Mean age was
54.14 ± 20.4 years. Positive cultures were obtained after a median hospital stay of 14 days. Most patients had
a history of surgery (57.6%), antibiotic use (95.6%), ICU stay (44.6%), indwelling lines (88.04%) and isolation
of another multi-resistant organism (52.2%).Most patients were symptomatic (70.7%). Amongst these, 38 had
candidemia while 27 had non-candidemia infections. Sites of infection included central lines (35), urinary
tract (19), peritonitis (4), nosocomial ventriculitis (1), empyema (1), fungal keratitis (1) otitis externa (1) and
surgical site (1). Fluconazole resistance was 100% while 28.5 and 7.9% were Voriconazole and Amphotericin resistant
respectively. Overall crude mortality was 42.4% while 14-day mortality was 31.5%. Both infected and colonized cases
shared similar mortality (46.2% vs 33.3%; p-value = 0.25). Among infected cases mortality was high in candidemia
compared to non-candidemia (60.5% vs 25.9%) in which deaths related to C. auris were 34.2% vs 22.2% respectively.
On multivariate analysis candidemia (AOR 4.2, 95% CI: 1.09–16.49; p-value = 0.037) was associated with greater mortality
with source control being the only protective factor for mortality (AOR 0.22, 95% CI: 0.05–0.92; p-value0.038] while ICU
stay, rapidity of blood culture clearance, DM, malignancy and MDR co-infection had no impact.
Conclusion: Patients with C.auris from a single center in Pakistan have a wide clinical spectrum with line associated
infection being the predominant site of infection. Candidemia leads to high mortality while source control improves
outcome.
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Background
Candida auris has emerged as an antifungal resistant
yeast causing invasive infections in nosocomial settings.
Improved diagnostics and epidemiological typing tech-
niques are essential to identify and characterize these
strains [1, 2]. It was first reported in Japan in 2009 when
it was isolated from external ear canal [3]. Later in 2011
it was reported for the first time as human pathogen
causing nosocomial fungemia in South Korea and
extremes of age with prior history of surgery was identi-
fied as a risk factor [4].C. auris was found to be closely
related to Candida haemulonii and was reported to be
misidentified as C. haemulonii using Vitek 2 YST and
Phoenix (BD). There are numerous other misidentifica-
tions using the commercially available diagnostic
methods. API 20CAUX misidentifies it as Rhodotorula
glutinis and C. sake. Vitek 2 (bioMe’rieux) misidentifies
it as C. haemulonii, C. lusitaniae and C. famata while
MicroScan (Beckman Coulter Pasadena, CA) misidenti-
fies this as C. famata, C. lusitaniae, C. guilliermondii, C.
parapsilosis, C. albicans and C. tropicalis [2]. This wrong
identification delayed its diagnosis, a finding later
endorsed by Kathuria S et al in 2015 [5]. It is notable
for its antifungal resistance creating a treatment
dilemma [6–8].
In September 2014, Aga Khan University Hospital, Ka-
rachi, Pakistan experienced an outbreak of a yeast which
was initially identified as Saccharomyces cerevisiae [9].
Because of the unusual antifungal susceptibility pattern
of this isolated yeast, these isolates were retested at the
Centers for Disease Control and Prevention (CDC), At-
lanta, USA for identification and were eventually identi-
fied as C. auris. Simultaneously this pathogen was
reported from India, South Africa and Venezuela and
came to lime light [9]. So far, the available literature has
emphasized on its methods of identification, antifungal
susceptibility and risk factors associated with acquisition.
Studies have shown that factors like extremes of age,
presence of co-morbidities and prior antifungal therapy
are associated with its acquisition while limited data
is available on its disease spectrum and outcomes.
Therefore, in this study, we have reported its clinical
spectrum, outcomes and outcome determining factors
among those with invasive infection. The aim of this
study was to assess the clinical spectrum and out-
come of patients, from a single center in Pakistan, in
whom C.auris was isolated.
Methods
We had conducted a retrospective study of 92 hospitalized
patients at the Aga Khan University Hospital (AKUH), a
600-bed tertiary care referral hospital located in Karachi,
Pakistan. All patients with C. auris positive culture from
September 2014–March 2017 were enrolled. Patients aged
< 16 years or those who did not receive primary treatment
at AKUH were excluded.
Cultures were processed by standard operating proce-
dures in use by the microbiology laboratory as part of
initial clinical work up. Any yeast from a sterile sample
was identified on the basis of germ tube test, appearance
on chromogenic medium BiGGY (Oxoid), cycloheximide
tolerance, microscopic morphology on Cornmeal Agar
(Dalmau method), and profile number on API 20C AUX
(bioMe’rieux). If identification was inconclusive (less
than 90% confidence on API), the antifungal susceptibility
results for Fluconazole and the API number generated
were taken into account. C. auris was presumptively iden-
tified by a combination of certain features: resistance to
fluconazole, absence of pseudo hyphae on thin Cornmeal
Tween80 agar, obtaining profile numbers 2,000,130,
2,000,173, 2,102,173, 6,102,173 on API 20C AUX (bio-
Me’rieux, France). This phenotype had been verified by
D1-D2 sequencing of 28S subunit of rDNA performed on
the first 15 isolates from our institute sent to the Mycotic
Diseases Branch, CDC, Atlanta. There was 100% concord-
ance between the described phenotype and sequencing
results. Antifungal susceptibility was tested using Sensiti-
treYeastOne (Trek Diagnostic Systems Ltd., East Grin-
stead, England) and E-test (bioMe’rieux SA, Marcy
l’Etoile, France). Susceptibilities against fluconazole, vori-
conazole, and amphotericin B were available for all iso-
lates. For an additional 28 isolates MIC values were also
available against itraconazole, posaconazole, anidulafun-
gin, micafungin and caspofungin. The susceptibilities were
interpreted for Candida species according to CLSI
M27-S3 for triazoles and echinocandins and M27-A3
guidelines for amphotericin B [10, 11]. Briefly, based on
these, the isolate was considered resistant to fluconazole if
MIC was ≥64 μg/ml, voriconazole if MIC was ≥4 μg/ml,
non-susceptible to amphotericin if MIC was > 1 μg/ml,
echinocandins if MIC was > 2 μg/ml. isolates were consid-
ered susceptible if MIC to fluconazole was ≤8 μg/ml, vori-
conazole was ≤1 μg/ml, amphotericin was ≤1 μg/ml, and
echinocandins was ≤2 μg/ml.
Demographic data including age, gender, date of
admission, unit type and a brief history including risk
factors (such as diabetes mellitus, malignancy, prior his-
tory of surgery, prior antibiotics or antifungal exposure,
prior ICU stay, indwelling lines and history of isolation
of any other multi-resistant organism), site of infection
and outcomes were collected using data collection
forms. Data was collected by the primary author only.
Patients with C. auris in cultures and associated clinical
sign and symptoms (including but not limited to fever,
site specific symptoms and relevant laboratory parame-
ters such as white blood cells and C-reactive protein)
were labeled as symptomatic/infected. On the other
hand, patients lacking associated clinical signs and
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symptoms with C. auris isolated from non-sterile sites
were considered asymptomatic/colonized. In case of
multiple positive cultures from the same patient the date
of first positive culture was considered as the date of in-
fection/colonization. The site of infection was labeled
using CDC definitions [12]. As candida is excluded from
CDC’s definition for urinary tract infections (UTI), this
was defined as clinical sign and symptoms of a UTI with
positive urine culture in the presence of urinary WBC
and absence of epithelial cells. Asymptomatic candiduria
was defined as presence of C. auris in urine without
clinical sign and symptoms. Standard criteria were used
for the definition of diabetes mellitus and malignancy.
Use of prior antimicrobials was defined as administra-
tion of any antibiotic/ antifungal in last 90 days of posi-
tive blood culture. Isolation of other multi-drug resistant
(MDR) bacteria before isolating C. auris was defined as
bacteria that were resistant to more than 3 classes of an-
tibiotics, isolated in last 90 days of positive blood culture
for C. auris while co infection with MDR bacteria was
their isolation within 7 days of positive culture for C.
auris. Whenever the given antifungal agent was in
standard-weight based dosage according to site of
infection, and when the isolate was reported as suscep-
tible to it on culture, antifungal therapy was considered
appropriate. This is in accordance with our institute’s
antifungal policy. For all invasive candida cases the first
line empiric antifungal therapy was intravenous Ampho-
tericin B deoxycholate 0.75 mg/kg. Lipid formulations of
amphotericin B were not used. Voriconazole was consid-
ered in cases with deranged renal functions when
amphotericin could not be administered. It was given in
a dose of 6 mg/kg 12 hourly on day 1 followed by 4 mg/
kg 12 hourly. Therapeutic drug monitoring for voricona-
zole was not available. Early appropriate antifungal ther-
apy was the appropriate antifungal therapy given in ≤48
h while late appropriate antifungal therapy was started
48 h after positive culture. Source control was defined as
the removal of inciting agent or focus and entailed the
removal of central line in case of Central Line Associ-
ated Blood Stream Infection (CLABSI), Foley’s catheter
in Catheter Associated Urinary Tract Infection (CAUTI),
exploratory laparotomy in peritonitis, drainage of pus
collection and removal of lumbar drain in ventriculitis.
Early source control was the removal of inciting agent in
≤48 h while late source control was when it was achieved
after 48 h of positive culture. Only crude mortality rate
(CMR) was assessed. Microbiological failure was consid-
ered in candidemia patients and was defined as failure to
clear blood culture within 4 days while clinical failure
was defined as 14-day mortality or microbiological fail-
ure. We considered 14-day mortality as there were large
number of patients who lost to follow-up during the
retrospective chart review. In patients who did not
survive, cause of death was also assessed by physicians
on clinical and laboratory evidence, and was thought to
be related to C. auris when other causes of death were
excluded and patient had an active C. auris infection at
that time.
We sought ethical approval from University’s Ethics Re-
view Committee (ERC number 4381-MED-ERC-2016).
The committee waived the requirement for informed con-
sent. To preserve confidentiality, we coded each patient
and removed their original identifications.
The collected data were analyzed through Statistical
Package for the Social Sciences (SPSS), version 22.0. For
continuous data, mean and standard deviation/ median
with interquartile range were reported depending on
normality assumption. For categorical data frequency
and percentage were reported. In order to assess associ-
ation of mortality with independent variables Chi square
test was applied and P value < 0.05 was considered sig-
nificant. Variables for univariate analysis were based on
known risk factors of mortality for invasive candidiasis
and on the preliminary analysis of our ongoing outbreak
study on C. auris [9, 13]. All statistically significant and
clinically relevant variables of univariate analysis were
included in a multivariate logistic regression analysis to
determine the independent predictive factors of mortal-
ity among infective C. auris cases. Results were given as
odds ratios (OR) and 95% confidence intervals (95% CI).
Results
From 2014 to 2017, 193 C. auris strains were isolated
from 92 patients with 16.3% confirmed as C. auris by
D1-D2 sequencing while rest were presumed to be C.
auris. The number of cases with C. auris rose over the
study period from 13 patients in the last quarter 2014 to
46 in 2016 (Fig. 1: Epi-curve of C. auris cases). Table 1
describes the baseline characteristics of the patients. The
median days from admission to positive culture was 14
(IQR-7-130). Most of the patients were older (median
age 55.5 years), were currently or previously admitted to
an Intensive Care Unit/ High Dependency Unit (ICU/
HDU), had indwelling lines (central lines and drains),
and received antibiotics. One in three patients (39.1%)
had also received antifungals in last 90 days of positive
culture. Fifty-two percent had MDR bacteria isolated
from different sites prior to C. auris while 31.5% had a
concomitant MDR bacterial infection.
Antifungal susceptibility was checked in isolates from
63 patients (68.4%) in which fluconazole resistance was
seen in all, voriconazole resistance in 18 (28.6%) and
amphotericin resistance seen in 5 (7.9%) patients. Iso-
lates from 3 patients (4.76%) were resistant to 2 classes
of antifungals (azoles and polyenes) while none were re-
sistant to all classes tested. No echinocandin resistance
was detected.
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Of the 193 C. auris strains, majority were isolated
from blood (75/193) and urine (83/193). Out of 83 urine
specimens 73 were from indwelling catheters, while 10
were mid-stream urine samples. Only 21 patients
(22.8%) isolated C. auris from 2 or more sites.
Of the 92 patients, 65 (70.7%) were infected while 27
(29.3%) were colonized with C. auris. Amongst the in-
fected patients, the most common site of infection was
the bloodstream accounting for 38 (41.3%) cases, most of
which were CLABSIs (35, 38.4%). Of the CLABSI patients,
9 (25.71%) were complicated by seeding to different
organs causing endovascular thrombosis or empyema.
Source of the fungemia could not be identified in 2 pa-
tients. Among non-candidemia patients, UTI was the
most commonly seen site infected (19 of 27 patients) with
11 having CAUTI and 8 non-catheter associated UTI.
Of the 65 infected patients, 55 were treated with anti-
fungals, amongst which only 44 patients (67.7%) received
the appropriate antifungal therapy. Early appropriate an-
tifungal therapy was administered to 20 (45.5%) patients.
Amongst the patients who received appropriate antifun-
gal therapy, majority received amphotericin alone (42,
95.5%) while 2 patients were treated with voriconazole
alone. However, 7 patients who initially received ampho-
tericin were later switched to voriconazole. Simultaneous
dual antifungal therapy was not given to any patient.
Out of 38 patients with candidemia, 31 (81.57%) re-
ceived appropriate antifungal therapy for a mean dur-
ation of 18.8 days. Only amphotericin was used to treat
candidemia. Early appropriate antifungals were adminis-
tered in 16 (51.6%) candidemia patients. However, mor-
tality was higher in those receiving early antifungals (11
of 16, 68.7%) compared to those who received antifun-
gals late (7 of 15; 46.7%). There were 7 patients who did
not receive antifungal therapy, of which 2 cleared their
candidemia with source control alone. Culture clearance
was achieved in 25 out of 27 patients in whom clearance
was checked. However, microbiological failure (i.e. lack
of clearance within 4 days) was seen in 11 patients.
Clearance could not be checked in 10 of the remaining
11 patients due to early mortality.
Amongst the 27 non-candidemia patients, 22 re-
ceived antifungal, of which 13 were appropriate. In
particular, of the 19 patients with UTI, 10 received
appropriate antifungal therapy for a mean duration of
12 days. In 8 (72.7%) of the 11 patients with CAUTI,
the catheter was removed. Five patients did not re-
ceive any antifungal, out of which 2 died within 24 h
of the positive culture. Patients with keratitis received
topical and systemic amphotericin while otitis externa
was managed with clotrimazole ear drops. Compared
to non-candidemia, candidemia patients had a higher
mortality rate (60.5% vs. 25.9%; p-value = 0.006) and
higher 14-day mortality (44.7% vs. 22.2%; p-value =
0.019).
Urine was the most common site of C. auris isolation
in asymptomatic patients (21/27) of whom 17 were cath-
eterized. While the catheter was removed in 10 of these
patients, repeat cultures were sent in 2 patients only,
both of which were negative. Table 2 compares charac-
teristics and outcomes of infected and colonized C. auris
cases. There was no difference in gender, age distribu-
tion, location in hospital, co-morbidities, co-infection
with MDR bacteria and probability of dying between the
two.
The median length of hospital stay in all patients was
25 days (IQR 1–163). The CMR was 39 (42.4%) in which
19 deaths (48.7%) were related to C. auris. The 14-day
mortality was 29 (31.5%) and the median days in which
mortality occurred was 7 (IQR 1–69).
Fig. 1 EPI-Curve of Candida Auris cases
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Table 3 shows details C. auris infective cases and mor-
tality impacting factors. The mean days in which mortal-
ity occurred was 5.26 days and 14- day mortality rate
was 94.7%.Compared to the infected survivors, these pa-
tients were more likely to be older (56–75 years, AOR
4.5, 95%CI:1.1–18.9) and had candidemia (AOR 4.2,
95%CI: 1.1–16.5). Survivors were also more likely to
have had adequate source control (AOR 0.2, 95%CI:
0.1–0.9).
Discussion
We describe the clinical characteristics and outcomes of
patients in whom C. auris was isolated in a single center
in Pakistan. We found a wide clinical spectrum ranging
from asymptomatic patients to invasive disease including
candidemia, urinary tract infections, empyema and ven-
triculitis. Most of the infections occurred in critically ill
patients who were admitted for a prolonged period of
time.
The crude in-hospital mortality was 42.4% which is
similar to the mortality rate seen in other studies ranging
from 35.2–60% [9, 14]. A total of 31.5% of the deaths were
related to C. auris infection, majority of whom died within
the first week of acquiring this. This high mortality rate is
in contrast with the UK outbreak reported by Schelenz
Table 1 Demographics of 92 patients with Candida auris
Category Total n = 92 (100%)
Male 48 (52.2%)
Age group
16–35 years 20 (21.7%)
36–55 years 26 (28.3%)
56–75 years 30 (32.6%)
76–96 years 16 (17.4%)
Location in hospital
ICU 30 (32.6%)
Special care 30 (32.6%)
Ward 27 (29.3%)
Outpatient 5 (5.4%)
Diabetes mellitus 26 (28.3%)
Malignancy 17 (18.5%)
Surgery 53 (57.6%)
Abdominal 12 (13%)
Cardiothoracic 8 (8.7%)
Neurosurgery 14 (15.2%)
ENT 9 (9.8%)
Orthopedics 7 (7.6%)
Others 2 (2.17%)
ICU stay in last 30 days 41 (44.6%)
Last ICU stay duration (weeks) ≤ 2 Weeks 31 (75.6%)
HDU stay in last 30 days 62 (67.4%)
Last HDU stay duration (weeks)
≤ 2 Weeks 52 (56.5%)
Indwelling lines 81 (88.04%)
Antibiotics in last 90 days 88 (95.6%)
Antifungals in last 90 days 36 (39.1%)
Fluconazole 19 (20.7%)
Voriconazole 3 (3.3%)
Amphotericin 7 (7.6%)
> 1 Antifungal 7 (7.6%)
Prior antifungal duration (weeks)
≤ 2 Weeks 25 (27.2%)
Isolation of multi-drug resistant bacteria
Prior toC.auris (≤ 90 days) 48 (52.2%)
Coinfection with C.auris 29 (31.5%)
Infected cases 65 (70.7%)
Candidemia 38 (58.5%)
Non-candidemia 27 (41.5%)
UTI 19
Peritonitis 3
Nosocomial ventriculitis 1
Empyema 1
Table 1 Demographics of 92 patients with Candida auris
(Continued)
Category Total n = 92 (100%)
Surgical Site Infection 1
Otitis externa 1
Keratitis 1
Colonized cases 27 (29.3%)
Asymptomatic candiduria 21
Central line tip 4
Ear Swab 1
Oral Swab 1
Antifungal resistance (n = 63)
Fluconazole 63 (100%)
Voriconazole 18 (28.57%)
Amphotericin 5 (7.93%)
Mean hospital stay (days) 30.73
Median hospital stay (days) 25 (1–163)
Mortality 39 (42.4%)
C auris death 19 (48.7%)
14-day mortality 29 (31.5%)
Mean days in which mortality occurred (days) 12.41
Median days in which mortality occurred (days) 7 (1–69)
Clinical failure 38 (41.3%)
Microbiological failure (Candidemia) 11 (40.74%)
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Setal where no deaths were directly attributable to C.
auris [15]. As expected candidemia patients had a higher
mortality, though interestingly, antifungal therapy did not
make a difference in the mortality. Also, paradoxically we
found that mortality was higher in those who received
early antifungal treatment; however this is likely reflective
of the severity of their illness which prompted rapid initi-
ation of amphotericin which is in contrast to other studies
[6, 16]. Moreover, we could not check if this difference
was statistically significant due to the small numbers in-
volved. Mortality was also higher in the older patients,
which has been shown in several other studies [15, 17,
18]. The most important factor impacting outcome was
adequate source control. This is in line with established
treatment guidelines for treating invasive candidiasis [19].
On the other hand, contrary to other studies, diabetes and
malignancy were not associated with mortality in our
study, possibly due to small numbers [14].
We found an annual increase in the number of identi-
fied cases at our institute. While patients with C.auris are
managed with barrier precautions, single room isolation is
not possible due to space constraints. Similarly, costs
preclude obtaining environmental and patient surveillance
cultures. As a result, clonal spread of our strains of C.auris
has been documented and highlights the challenges of
infection prevention in resource limited countries [9].
Despite skepticism regarding the propensity of C. auris
to cause urinary tract infection or empyema as stated by
CDC, we have found that UTI was the second most
common site for symptomatic infection [20]. Moreover,
we describe several unusual infection sites including
wound, peritoneum, otitis externa, keratitis, ventriculitis
and empyema. However, as expected bloodstream infec-
tion, in particular CLABSI was the most common infec-
tion seen.
The strength of our study is the large number of pa-
tients with comprehensive clinical data, giving a better
understanding of the spectrum of disease caused by
C.auris. Moreover, this is the largest series looking at the
gamut of infections caused by the South Asian strain of
C.auris in both ICU and non-ICU patients. However,
our study has several limitations. Firstly, the data was
retrospectively collected leading to potential information
bias. Secondly, and perhaps more importantly, not all of
our C. auris isolates were confirmed by sequencing.
However, the characteristic phenotype we have described
had 100% concordance in the 15 strains in which D1-D2
sequencing was performed. Similarly, we were unable to
perform genetic antifungal resistance testing. However,
of the 15 strains from Pakistan which underwent whole
genome sequencing 2 distinct ERG 11 hotspot mutations
were identified: Y123F and K143R [9].
Table 2 Comparison of C. auris infected patients with C. auris colonizers
Variable Infection (n = 65) Colonization (n = 27) p-value
Male 35 (53.8%) 13 (48.1%) 0.85
Age group
16–35 15 (23.1%) 5 (18.5%)
36–55 20 (30.8%) 6 (22.2%) 0.51
56–75 21 (32.3%) 9 (33.3%)
76–95 9 (13.8%) 7 (25.9%)
ICU 23 (35.4%) 7 (25.9%) 0.12
HDU 24 (36.9%) 6 (22.2%)
Ward 11 (40.7%) 16 (24.6%)
DM 18 (27.7%) 8 (29.6%) 0.85
Malignancy 13 (20%) 5 (18.5%) 0.80
Surgery 39 (60%) 14 (51.9%) 0.61
Co-infection with MDR bacteria 22 (33.8%) 7 (25.9%) 0.45
Appropriate antifungal therapy 44 (67.7%) 0 < 0.001
Source control 40 (61.5%) 7 (25.9%) < 0.001
Mortality 30 (46.2%) 9 (33.3%) 0.25
14-day mortality 23 (35.4%) 6 (22.2%) 0.45
Clinical failure 24 (64.9%) 6 (22.2%) < 0.001
Alive 35 (53.8%) 18 (66.7%)
C. auris death 19 (29.2%) 0
Non-auris death 11 (16.9%) 9 (33.3%) 0.005
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Conclusion
In conclusion, C.auris is associated with a wide variety
of invasive infections and carries a high mortality rate.
Source control is the most effective therapeutic inter-
vention to reduce mortality in these critically ill patients.
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ICU 14 (46.7%) 09 (25.7%) 3.4 [0.8–13] 0.07 1.2 [0.24–5.8] 0.81
Special Care 11 (36.7%) 13 (37.1%) 1.86 [0.5–7.0] 0.35
Ward 05 (16.7%) 11 (31.4%) 1.0 0.19
Outpatient 0 02 (3.1%)
Diabetes Mellitus 11 (36.7%) 07 (20%) 2.3 [0.7–7.0] 0.13
Malignancy 06 (20%) 06 (17.6%) 0.96 [0.20–3.2] 0.95
Candidemia 23 (76.7%) 15 (42.9%) 4.3 [1.4–12] 0.007 4.2 [1.09–16.49] 0.03
Early blood clearance (≤72 h) 02 (18.2%) 5 (35.7%) 1.0
Late blood clearance (> 72 h) 09 (81.8%) 9 (64.3%) 2.5 [0.38–16.42] 0.34
No blood clearance 02 (15.4%) 0 (0)
Appropriate antifungal therapy 23 (76.7%) 21 (60%) 2.2 [0.7–6.4] 0.15
Early antifungal therapy 14 (46.7%) 6 (17.1%) 4.66 [1.2–17.43] 0.02 0.84 [0.16–4.3] 0.83
Late antifungal therapy 09 (30%) 15 (42.9%) 1.2 [0.3–4.09] 0.77 4.1 [0.94–17.9] 0.06
Source control 17 (42.5%) 25 (57.5%) 0.52 [0.18–1.46] 0.2 0.22 [0.05–0.92] 0.038
Early source control 07 (41.2%) 13 (56.5%) 1.0
Late source control 10 (58.8%) 10 (43.5%) 1.5 [0.4–5.3] 0.49
Co infection with multidrug resistant bacteria 13 (43.3%) 09 (25.7%) 2.2 [0.77–6.2] 0.13 2.7 [0.61–12.6] 0.18
*OR, odds ratio
†AOR, adjusted odds ratio
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